Maria Fardis Net Worth

Maria Fardis biography

Dr. Maria Fardis Ph.D. serves as President, Chief Executive Officer and Director of the Company. Dr. Fardis served as the Chief Operating Officer of Acerta Pharma, LLC, a clinical-stage biopharmaceutical company, from January 2015 to March 2016. From 2011 to 2014, she worked at Pharmacyclics, Inc., which she joined as Senior Director of Global Project Management, and was promoted to Vice President, Alliance and Global Project Management in December 2011, was appointed Executive Vice President, Alliances and Operations in September 2012 and was appointed Chief of Oncology Operations and Alliances in March 2013. Prior to joining Pharmacyclics, from August 2001 to April 2011, Dr. Fardis held increasingly senior positions in Medicinal Chemistry and the project and portfolio management department at Gilead Sciences, Inc., most recently serving as Associate Director, Project and Portfolio Management. Dr. Fardis received her Ph.D. in Organic Chemistry from the University of California, Berkeley and her B.S. summa cum laude, in chemistry from the University of Illinois, Urbana-Champaign. Dr. Fardis holds an MBA, with highest honors, from Golden Gate University.

What is the salary of Maria Fardis?

As the President y Chief Executive Officer and Director of Iovance Biotherapeutics Inc, the total compensation of Maria Fardis at Iovance Biotherapeutics Inc is $4,107,960. There are no executives at Iovance Biotherapeutics Inc getting paid more.

How old is Maria Fardis?

Maria Fardis is 52, he's been the President y Chief Executive Officer and Director of Iovance Biotherapeutics Inc since 2016. There are 8 older and 6 younger executives at Iovance Biotherapeutics Inc. The oldest executive at Iovance Biotherapeutics Inc is Merrill McPeak, 84, who is the Independent Director.

What's Maria Fardis's mailing address?

Maria's mailing address filed with the SEC is C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON, MA, 02127.

Insiders trading at Iovance Biotherapeutics Inc

Over the last 8 years, insiders at Iovance Biotherapeutics Inc have traded over $0 worth of Iovance Biotherapeutics Inc stock and bought 22,614,553 units worth $159,655,586 . The most active insiders traders include Wayne P. Rothbaum, Merrill A Mcpeak y Timothy E Morris. On average, Iovance Biotherapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $3,815,146. The most recent stock trade was executed by Frederick G Vogt on 3 September 2024, trading 57,292 units of IOVA stock currently worth $535,680.

What does Iovance Biotherapeutics Inc do?

iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical

Iovance Biotherapeutics Inc executives and stock owners

Iovance Biotherapeutics Inc executives and other stock owners filed with the SEC include:

• Maria Fardis,
  President, Chief Executive Officer and Director
• Friedrich Graf Finckenstein,
  Chief Medical Officer
• Frederick Vogt,
  General Counsel, Corporate Secretary
• Iain Dukes,
  Chairman of the Board
• Michael Weiser,
  Independent Director
• Jean-Marc Bellemin M.B.A.,
  Chief Financial Officer & Principal Accounting Officer
• Dr. Friedrich Graf Finckenstein M.D.,
  Chief Medical Officer
• Dr. Frederick G. Vogt Esq., J.D., Ph.D.,
  Interim Pres, CEO, Gen. Counsel & Corp. Sec.
• Merrill McPeak,
  Independent Director
• Ryan Maynard,
  Independent Director
• Athena Countouriotis,
  Director
• Michael Swartzburg,
  Interim Principal Financial Officer and Principal Accounting Officer
• Sara Pellegrino,
  IR Contact Officer
• Wayne Rothbaum,
  Independent Director
• Dr. Elma S. Hawkins,
  Advisor to the Board
• Madan Jagasia,
  Sr. VP of Medical Affairs
• James Ziegler,
  Sr. VP of Commercial
• Howard B. Johnson,
  Sr. VP of Corp. Devel., Alliance Management & Program Management
• Dr. Igor P. Bilinsky,
  Chief Operating Officer
• Timothy E Morris,
  Chief Financial Officer
• Jean Marc Bellemin,
  Chief Financial Officer
• Igor Bilinsky,
  Chief Operating Officer
• Wendy L Yarno,
  Director
• Wendy L Dixon,
  Director